| Website | scpvitalife.com |
| Phone | (610) 995-2900 |
| info@scpvitalife.com | |
| Employees | |
| Founded | 2002 |
| Description | Venture Capital |
SCP Vitalife is a Life Sciences Fund formed by SCP Partners , a U.S.-based investment organization with over $900 million in venture funds under management, and Vitalife , an experienced venture firm investing primarily in Israeli medical technology companies. The SCP Vitalife team includes investment professionals with prior experiences as senior executives, clinical practitioners and venture capitalists.
Our focus is on early to mid-stage life science technologies and services, with a concentration on therapeutic medical devices.
We will continue to follow the successful formula of our predecessor fund, Vitalife Life Sciences Fund, offering our portfolio companies hands-on strategic assistance in planning, operations and finance. From our investment experience we have developed extensive networks to access capital, recruit management and facilitate favorable strategic alliances.
| Company | Date | Round | Size | Participants |
| Avedro | 3/13 | Series D | $43M | 8 |
| Regentis Biomaterials | 5/12 | Series C | $10M | 3 |
| Avedro | 2/12 | Venture Round | $500k | 2 |
| Fluidnet | 8/11 | Series C | $25M | 5 |
| Avedro | 7/11 | Series C | $25M | 2 |
| Niti Surgical Solutions | 8/09 | Series F | $18.5M | 6 |
| Garnet Biotherapeutics | 2/09 | Series A | $10.4M | 3 |
